The Patent Finder

Tris Pharma, Inc.

55 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
17
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 6, 2026
    The maintenance fee for GHB Pharmaceutical Compositions Comprising a Floating Interpenetrating Polymer Network Forming System (US 11,666,546) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 2 fees due May 10, 2027
  • 1 fee due Jun 17, 2027
    The maintenance fee for Methylphenidate Extended Release Chewable Tablet (US 10,507,203) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Benzonatate Modified Release Solid Tablets and Capsules (US 11,890,267) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 3 fees due Sep 5 to 29, 2027 · next Sep 5

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,202,537Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 8,337,890Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 8,597,684Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 8,747,902Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 8,790,700Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 8,883,217Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 9,198,864Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 9,549,989Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 9,675,703Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
US 9,675,704Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes
In force
 · High confidence
In forceHigh confidence
10 of 55 patents shown.
Pro members see all 55.
Pro members: see all 55 patents
Also on record, not counted in the 55: 3 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 6 abandoned · 13 no status recorded

Showing 1 to 10 of 24, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/975,337Dec 10, 2024No status recorded
18/781,325Extended Release Amphetamine TabletsJul 23, 2024Pending
18/589,177Methods for Improving Driving BehaviorFeb 27, 2024Pending
18/302,525GHB Pharmaceutical Compositions Comprising a Floating Interpenetrating Polymer Network Forming SystemApr 18, 2023Pending
18/184,443Methylphenidate Extended Release Chewable TabletMar 15, 2023Abandoned
18/156,931Extended Release Amphetamine CompositionsJan 19, 2023Pending
18/061,004Novel Clonidine FormulationDec 2, 2022Abandoned
17/818,733Oxybate Polyethylene Glycol ProdrugsAug 10, 2022Pending
17/675,842Modified Release Formulations Containing Drug-Ion Exchange Resin ComplexesFeb 18, 2022Abandoned
17/147,200Jan 12, 2021No status recorded
10 of 24 applications shown.
Pro members see all 24 published applications.
Pro members: see all 24 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited